Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1449 • ACR Convergence 2022
Incidence and Risk Factors for Active Tuberculosis in Patients with Systemic Lupus Erythematosus: A Multicenter Prospective Cohort Study
Lifan Zhang¹, xiaoqing zou², Lantian Xie³, Jianghao Liu³, zhengrong yang⁴, qifei cao⁴, Chunlei Li⁵, Xiaochuan Sun⁵, Fengchun ZHANG⁶, Yan Zhao⁷, Xiaofeng Zeng⁸ and Xiaoqing Liu¹, ¹Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Clinical Epidemiology Unit, Peking Union Medical College, International Clinical Epidemiology Network; Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China, ⁴Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁵Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁶Peking Union Medical College Hospital, Beijing, China, ⁷Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China, ⁸Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: The burden of tuberculosis (TB) and systemic lupus erythematosus (SLE) in China are both the second largest in the world. Patients with SLE are…
Abstract Number: 1468 • ACR Convergence 2022
Apathy Measurement in a Cohort of Systemic Lupus Erythematosus
Mike Putman¹, David Gazeley² and Ikechukwu Mbonu³, ¹The Medical College of Wisconsin, Milwaukee, WI, ²Medical College of Wisconsin, Wauwatosa, WI, ³Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Up to 40% of patients with systemic lupus erythematosus (SLE) have measurable cognitive dysfunction on neuropsychiatric testing. Around 83% of patients are nonadherent with…
Abstract Number: 1538 • ACR Convergence 2022
Decreased Prevalence of Autoimmune Connective Tissue Diseases in Type 1 and Type 2 Diabetes
Aya abugharbyeh, Sadik Khuder and bashar Kahaleh, University of Toledo, Toledo, OH
Background/Purpose: Evidence suggest that autoimmune diseases tend to coexist at a higher rate than expected, reflecting a common pathogenetic pathway. However, data sets have shown…
Abstract Number: 1692 • ACR Convergence 2022
Interferon Alpha Promotes Ultraviolet Light-Mediated Keratinocyte Apoptosis in a Caspase-8 Dependent Manner via Upregulation of Interferon Regulatory Factor 1
Shannon Estadt, Mehrnaz Gharaee-Kermani, Bin Xu, Tyson Moore, Andrew Hannoudi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by enhanced sensitivity to ultraviolet radiation (UVR). UVR can trigger cutaneous and systemic disease…
Abstract Number: 1726 • ACR Convergence 2022
Impaired Dynamic X-Chromosome Inactivation Maintenance in T Lymphocytes Is a Feature of Spontaneous Lupus in Female Mice and Is Exacerbated in Female-Biased Disease Models
Nikhil Jiwrajka¹, Natalie Toothacre², Zachary Beethem², Sarah Sting², Katherine Forsyth², Amanda Driscoll², William Stohl³ and Montserrat Anguera², ¹Division of Rheumatology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Department of Biomedical Sciences, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, ³University of Southern California, Los Angeles, CA
Background/Purpose: SLE is highly female-biased, yet the molecular origins of this bias remain unclear. The X chromosome contains many immune-related genes, suggesting that X-linked epigenetic…
Abstract Number: 2056 • ACR Convergence 2022
Long Term Safety and Effectiveness of Belimumab Therapy in Patient with SLE: A Single Center Retrospective Analysis
Takehiro Nakai¹, Sho Fukui², Takahiro Asano³, Futoshi Iwata⁴, Hiroki Ozawa⁵, Satoshi Kawaai⁴, Yukihiko Ikeda¹, Hiromichi Tamaki¹, Mitsumasa Kishimoto⁶, Kenichi YAMAGUCHI⁷ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Kyorin University Hospital, Tokyo, Japan, ³St. Luke's International Hospital, Chuo City Tokyo, Japan, ⁴St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ⁵Immuno-Rheumatology Center, St.Luke's International Hospital, Tokyo, Japan, ⁶Kyorin University School of Medicine, Yokohama, Japan, ⁷St.Luke's International Hospital, Tokyo, Japan
Background/Purpose: Many clinicians use belimumab as a maintenance therapy of SLE, but there is scarce data on belimumab drug retention rate and safety/effectiveness profile in…
Abstract Number: 2074 • ACR Convergence 2022
Poor Executive Function Correlates with Increased Disease Damage and Impaired Patient-Reported Outcomes in Youth with Childhood-Onset Lupus: A Cross-Sectional Study
Tala El Tal¹, Santiago Arciniegas², Sarah Mossad³, Ibrahim Mohamed⁴, Victoria Lishak⁵, Stephanie Fevrier⁶, Lawrence Ng³, Paris Moaf³, Joanna Law³, ashley Danguecan³, Linda Hiraki⁷, Deborah Levy⁸ and Andrea Knight¹, ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ²University of Toronto/Hospital for Sick Children, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, ON, Canada 3Institute of Biomedical Engineering, University of Toronto, Brampton, ON, Canada, ⁵The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ⁶The Hospital for Sick Children/University of Toronto, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Cognitive dysfunction affects up to 60% of youth with childhood-onset systemic lupus erythematosus (cSLE), particularly executive dysfunction (ED), with adverse effects on treatment adherence,…
Abstract Number: 2092 • ACR Convergence 2022
Greater Social Vulnerability Associates with Greater Glucocorticoid Use in Patients with SLE
Avira Som¹, Lily McMorrow¹, Ling Chen¹, Deepali Sen¹, Alia El-Qunni¹, Elizabeth Baker² and Alfred Kim¹, ¹Washington University School of Medicine, St. Louis, MO, ²Saint Louis University College for Public Health and Social Justice, St. Louis, MO
Background/Purpose: Patients with SLE experience substantial health disparities. Studying the effect of spatial context on health outcomes has become a focus in health disparities research.…
Abstract Number: 2191 • ACR Convergence 2022
Long-term Outcomes of Children Born to Mothers with Systemic Lupus Erythematosus: A Nationwide Population-based Study in Korea
In Ah Choi¹, Ji Hyoun Kim², Sung Hae Chang³, Hyun Jung Kim⁴ and Hyeong Sik Ahn⁴, ¹Chungbuk National University, Cheongju, Republic of Korea, ²Chungbuk National University Hospital, Cheongju, Republic of Korea, ³Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, Republic of Korea, ⁴Institute for Evidence-based Medicine, Cochrane Korea, Seoul, Republic of Korea
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that primarily affects women of childbearing age, and epidemiologic studies have shown poor maternal and fetal…
Abstract Number: 0099 • ACR Convergence 2022
Impact of Multimodal Independent Medical Education on Improving Outcomes and Reducing Disparities in Systemic Lupus Erythematosus and Lupus Nephritis
Lisa Handley¹, Kimberly Lovin Nealy² and Sarah A. Nisly³, ¹Clinical Care Options, Clive, IA, ²Clinical Care Options, Matthews, NC, ³Clinical Care Options, Reston, VA
Background/Purpose: Due to its range of manifestations and lack of specific findings, early diagnosis of SLE is often a challenge, and serious complications, including LN,…
Abstract Number: 0320 • ACR Convergence 2022
Metabolomics in Systemic Lupus Erythematosus and Pregnancy – A Prospective Observational Longitudinal Study
Shi-Nan Luong¹, Isabella Sheldon², Charles Raine³, Elizabeth Jury³ and Ian Giles³, ¹University College London, United Kingdom and University of New South Wales, Sydney, Australia, ²London School of Hygiene and Tropical Medicine, London, United Kingdom, ³University College London, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by activation of immunological and cellular pathways, disease flares and adverse pregnancy outcomes (APO). Metabolomic…
Abstract Number: 0339 • ACR Convergence 2022
Corneal Confocal Microscopy: A Potential Ophthalmic Imaging Biomarker of Neurodegeneration for Systemic Lupus Erythematosus
Miral H.Gharib¹, Georgios Baloglu², Soha Osman¹, Rayaz A.Malik³ and Samar Al emadi¹, ¹Hamad Medical Corporation, Doha, Qatar, ²Weill Cornell Medicine-Qatar, Research division, Qatar foundation, Doha, Qatar, ³Weill Cornell Medicine-Qatar, Research division, Qatar foundation, institute of cardiovascular sciences, Cardiac center, university of Manchester and NIHR clinical research facility, Doha, Qatar
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multi-system autoimmune disease with frequent neuropsychiatric symptoms occurring in 80% to 90% of patients with SLE divided…
Abstract Number: 0360 • ACR Convergence 2022
Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus
Mark Lazarus¹, Paul Newcombe¹, Richard A. Furie², Philip Brohawn³, Wendy White³, Dominic Sinibaldi³, Nicola Ferrari¹, Raj Tummala³, Hussein Al-Mossawi¹, Edward Vital⁴, Eric F. Morand⁵, Daniel Muthas⁶ and Madhu Ramaswamy³, ¹AstraZeneca, Cambridge, United Kingdom, ²Northwell Health, Great Neck, NY, ³AstraZeneca, Gaithersburg, MD, ⁴University of Leeds, Leeds, England, United Kingdom, ⁵Monash University, Melbourne, Australia, ⁶AstraZeneca, Gothenburg, Sweden
Background/Purpose: Phase 2/3 clinical trials in patients with moderate to severe SLE have demonstrated that anifrolumab, a monoclonal antibody blocking IFNAR1, produced better clinical outcomes…
Abstract Number: 0570 • ACR Convergence 2022
Clarifying Misbeliefs About Hydroxychloroquine (HCQ): Developing an Evidence-Based HCQ Benefits vs. Risk Decision Aid (HCQ-SAFE) Per Low Health Literacy Standards
Shivani Garg¹, Sancia Ferguson², Betty Chewning³, Shelby Gomez⁴, Jon Keevil⁵ and Christie Bartels⁶, ¹University of Madison, School of Medicine and Public Health, Madison, WI, ²University of Wisconsin School of Medicine & Public Health, Madison, WI, ³University of Wisconsin, School of Pharmacy, Madison, WI, ⁴UW Health, Stoughton, WI, ⁵NA, Madison, WI, ⁶University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Studies report ~83% of SLE patients discontinue hydroxychloroquine (HCQ) and many report suboptimal shared decision-making with their healthcare team. Moreover, patients report knowledge gaps…
Abstract Number: 0643 • ACR Convergence 2022
Subsetting SLE Patients Based on DNA Methylation at the Time of Disease Flare
Mary Horton¹, Joanne Nitithalm², Kimberly Taylor³, Laura Trupin⁴, Patricia Katz⁵, Jinoos Yazdany⁶, Maria Dall'Era⁷, Lisa Barcellos⁸, Lindsey Criswell⁹ and Cristina M Lanata¹⁰, ¹NIH/NHGRI, Oakland, CA, ²NIH/NHGRI, Bethesda, MD, ³University of Californi, San Francisco, San Francisco, CA, ⁴UC San Francisco, San Francisco, CA, ⁵UCSF, San Rafael, CA, ⁶UCSF, San Francisco, CA, ⁷University of California, Division of Rheumatology, San Francisco, CA, ⁸School of Public Health, UC Berkeley; National Human Genome Research Institute, National Institutes of Health, Berkeley, CA, ⁹National Human Genome Research Institute, NIH, Bethesda, MD, ¹⁰NIH/NHGRI, Washington, DC
Background/Purpose: Current treatments for SLE do not adequately prevent disease progression. This lack of efficacy, in part, relates to the molecular heterogeneity of disease. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].